| Autor: |
C, Bessy, T, Blin, E, Pichon, S, Marchand-Adam, D, Carmier |
| Jazyk: |
francouzština |
| Rok vydání: |
2022 |
| Zdroj: |
Revue des maladies respiratoires. |
| ISSN: |
1776-2588 |
| Popis: |
Following the CodeBreak 100 study, since 2021 sotorasib has been available in France, with authorization for early access in treatment of non-small cell lung cancer with a KRAS G12C mutation. Our retrospective observational study was designed to determine the efficacy and safety of sotorasib under real-life conditions in patients treated at the Tours CHRU. Our study of 15 patients showed sotorasib to be effective in 47% of cases, with overall survival of 4 months and median progression-free survival of 5.5 months for responders. Tumor control was achieved in 7/8 (87%) of patients with PS of 0 or 1 and in 1/7 (14%) of patients with a PS of 2 or greater. Grade 3 acute hepatitis occurred in 3/15 patients (20%). While sotorasib is an interesting therapeutic option, with efficacy that seems better in patients in good general condition, it entails a possible risk of drug-induced hepatitis, which remains to be specified in dedicated studies. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
